No Data
No Data
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
Cardiol Therapeutics Prices $13.5M Public Offering | TSX:CRDL, NASDAQ:CRDL
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Cardiol Therapeutics Achieves Target Patient Enrollment in Its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis With Results to Be Presented at the American Heart Association Scientific Sessions 2024
No Data